Hepatic Encephalopathy Clinical Trial
Official title:
Role of Magnetic Resonance Imaging in Detection of Minimal Hepatic Encephalopathy
Introduction Liver cirrhosis (LC) is irreversible fibrosis of the liver (1) and it remains a
public health problem. One of the complications of the cirrhosis is hepatic encephalopathy
(HE) which is defined as brain dysfunction caused by liver insufficiency. Pathophysiological
mechanisms of HE are complex and multifactorial. Recognition of beginning stages of HE, such
as minimal HE (mHE) is of most importance.
Objectives and originality of the project Diagnosis of mHE can be challenging, time-consuming
and, at least to some extent, subjective. This project will assess the role of magnetic
resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique. With advanced
magnetic resonance (MR) techniques, in-vivo detection of intracellular water content,
estimation pH and metabolites levels with millimolar concentrations can be easily performed.
This will offer to explore possible pathophysiological mechanisms of HE and to evaluate the
results from previous, studies that were mainly performed on animal models or cell cultures.
By our best knowledge, multimodal MR approach as the investigators propose in this
application has not been yet performed. The investigators will use advanced MR techniques
which are currently not available in the clinical setting and require multicenter
collaboration.
Methods The investigators will include 10-20 patients of both genders with hyperammonemia and
mHE and 10-20 patients of both genders with HE. Diagnosis of HE will be made based on results
of validated neuropsychiatric test. Age-matched and gender-matched control group with no
gastrointestinal, neurological or psychiatric complaints and normal levels of ammonia in the
blood. Patients with mHE/HE will be included from outpatient clinic of the Department of
gastroenterology, University Medical Centre (UMC) Ljubljana. Healthy controls (HC) will be
invited to join via internet advertisement. Contraindications for HC will include
gastrointestinal (emphasis on liver disease), neurological or psychiatric complaints. Grade
of mHE/HE will be classified according to West-Haven (WH) classification. Patients with
different degree of liver cirrhosis, which will be scored with the Child-Pugh (CP) score, and
with no contraindications for MR (e.g. presence of metal in body) will be included. Blood
levels of liver enzymes and ammonia will be measured in all participants. MR scanning will
include: T1- and T2-weighted MR, MRS (MEGA-PRESS and PRESS) in two voxels: striatum and
cerebellum. Location will be double-checked by voxel position screenshots. Analysis, with
voxel-positioning error compensation will be performed in Gannet (www.gabamrs.com). Moreover,
high resolution diffusion weighted imaging (DWI), diffusion kurtosis imaging (DKI),
quantitative susceptibility mapping (QSM) will be performed in brain as well. Liver QSM will
be executed to assess iron load.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | June 1, 2023 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Known liver disease/cirrhosis Exclusion Criteria: - Pregnancy, non compatible material with MRI |
Country | Name | City | State |
---|---|---|---|
Slovenia | Department of Gastroenterology and Hepatology, University Medical Centre Ljubljana | Ljubljana |
Lead Sponsor | Collaborator |
---|---|
University Medical Centre Ljubljana | Johns Hopkins University, Medical University of Graz, University of Ljubljana, Faculty of Medicine |
Slovenia,
Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006 Oct;44(4):788-94. Review. — View Citation
American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014 Sep;61(3):642-59. doi: 10.1016/j.jhep.2014.05.042. Epub 2014 Jul 8. Review. Erratum in: J Hepatol. 2015 Oct;63(4):1055. — View Citation
Bartolic M, Vovk A, Ĺ uput D. Effects of NH(4)CL application and removal on astrocytes and endothelial cells. Cell Mol Biol Lett. 2016 Aug 23;21:13. doi: 10.1186/s11658-016-0011-3. eCollection 2016. — View Citation
Binesh N, Huda A, Bugbee M, Gupta R, Rasgon N, Kumar A, Green M, Han S, Thomas MA. Adding another spectral dimension to 1H magnetic resonance spectroscopy of hepatic encephalopathy. J Magn Reson Imaging. 2005 Apr;21(4):398-405. — View Citation
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593-608. doi: 10.1016/j.jhep.2012.12.005. Review. — View Citation
Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodés J. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999 May;30(5):890-5. — View Citation
Chavarria L, Alonso J, García-Martínez R, Simón-Talero M, Ventura-Cots M, Ramírez C, Torrens M, Vargas V, Rovira A, Córdoba J. Brain magnetic resonance spectroscopy in episodic hepatic encephalopathy. J Cereb Blood Flow Metab. 2013 Feb;33(2):272-7. doi: 10.1038/jcbfm.2012.173. Epub 2012 Nov 21. — View Citation
Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999 Feb;9(2):179-94. — View Citation
Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017 Jun 28;5(2):142-151. doi: 10.14218/JCTH.2016.00069. Epub 2017 May 4. Review. — View Citation
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002 Mar;35(3):716-21. — View Citation
Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5. — View Citation
Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002 Jan 31;33(3):341-55. — View Citation
Fischl B, Salat DH, van der Kouwe AJ, Makris N, Ségonne F, Quinn BT, Dale AM. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23 Suppl 1:S69-84. — View Citation
Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999 Feb;9(2):195-207. — View Citation
Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp. 1999;8(4):272-84. — View Citation
Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, Caviness V, Makris N, Rosen B, Dale AM. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004 Jan;14(1):11-22. — View Citation
Foerster BR, Conklin LS, Petrou M, Barker PB, Schwarz KB. Minimal hepatic encephalopathy in children: evaluation with proton MR spectroscopy. AJNR Am J Neuroradiol. 2009 Sep;30(8):1610-3. doi: 10.3174/ajnr.A1652. Epub 2009 Jun 9. — View Citation
Ge PS, Runyon BA. Treatment of Patients with Cirrhosis. N Engl J Med. 2016 Aug 25;375(8):767-77. doi: 10.1056/NEJMra1504367. Review. — View Citation
Geissler A, Lock G, Fründ R, Held P, Hollerbach S, Andus T, Schölmerich J, Feuerbach S, Holstege A. Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. Hepatology. 1997 Jan;25(1):48-54. — View Citation
Harris AD, Saleh MG, Edden RA. Edited (1) H magnetic resonance spectroscopy in vivo: Methods and metabolites. Magn Reson Med. 2017 Apr;77(4):1377-1389. doi: 10.1002/mrm.26619. Epub 2017 Feb 2. Review. — View Citation
Hassan EA, Abd El-Rehim AS, Seifeldein GS, Shehata GA. Minimal hepatic encephalopathy in patients with liver cirrhosis: magnetic resonance spectroscopic brain findings versus neuropsychological changes. Arab J Gastroenterol. 2014 Sep-Dec;15(3-4):108-13. doi: 10.1016/j.ajg.2014.09.003. Epub 2014 Nov 11. — View Citation
Häussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, Gerok W, Hennig J. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 1994 Nov;107(5):1475-80. — View Citation
Laubenberger J, Häussinger D, Bayer S, Gufler H, Hennig J, Langer M. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology. 1997 May;112(5):1610-6. — View Citation
Lee JH, Seo DW, Lee YS, Kim ST, Mun CW, Lim TH, Min YI, Suh DJ. Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve. Am J Gastroenterol. 1999 Aug;94(8):2206-13. — View Citation
Long LL, Li XR, Huang ZK, Jiang YM, Fu SX, Zheng W. Relationship between changes in brain MRI and (1)H-MRS, severity of chronic liver damage, and recovery after liver transplantation. Exp Biol Med (Maywood). 2009 Sep;234(9):1075-85. doi: 10.3181/0903-RM-118. Epub 2009 Jun 22. — View Citation
Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018 Feb;38 Suppl 1:2-6. doi: 10.1111/liv.13682. Review. — View Citation
Mechtcheriakov S, Schocke M, Kugener A, Graziadei IW, Mattedi M, Hinterhuber H, Vogel W, Marksteiner J. Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy. Neuroradiology. 2005 Jan;47(1):27-34. Epub 2005 Jan 18. — View Citation
Miese F, Kircheis G, Wittsack HJ, Wenserski F, Hemker J, Mödder U, Häussinger D, Cohnen M. 1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. AJNR Am J Neuroradiol. 2006 May;27(5):1019-26. — View Citation
Ochoa-Sanchez R, Rose CF. Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease. J Clin Exp Hepatol. 2018 Sep;8(3):262-271. doi: 10.1016/j.jceh.2018.08.001. Epub 2018 Aug 18. Review. — View Citation
Oeltzschner G, Butz M, Baumgarten TJ, Hoogenboom N, Wittsack HJ, Schnitzler A. Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes. Metab Brain Dis. 2015 Dec;30(6):1429-38. doi: 10.1007/s11011-015-9729-2. Epub 2015 Sep 11. — View Citation
* Note: There are 30 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Structural and Functional Changes in Brain Structures with Magnetic Resonance Imaging | GABA levels and other neurotransmitters with respect to the tissue water signal and corrected for tissue composition. | 2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01559519 -
Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
|
Phase 4 | |
Terminated |
NCT01846806 -
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
|
N/A | |
Recruiting |
NCT01178372 -
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
|
Phase 4 | |
Completed |
NCT00914056 -
A Study of Controlled Lactulose Withdrawal
|
N/A | |
Completed |
NCT00740142 -
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
|
Phase 4 | |
Completed |
NCT00558038 -
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
Recruiting |
NCT05539027 -
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy
|
Phase 4 | |
Recruiting |
NCT04096014 -
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
|
N/A | |
Completed |
NCT05526404 -
Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Enrolling by invitation |
NCT06367127 -
Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
|
||
Active, not recruiting |
NCT05425316 -
Speech in Hepatic Encephalopathy (HE)
|
||
Recruiting |
NCT04415294 -
Flicker App for Minimal Hepatic Encephalopathy
|
||
Not yet recruiting |
NCT06072521 -
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
|
Phase 2 | |
Withdrawn |
NCT02086825 -
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
|
Phase 3 | |
Completed |
NCT02636647 -
Fecal Transplant in Recurrent Hepatic Encephalopathy
|
Phase 1 | |
Completed |
NCT01446523 -
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
|
N/A | |
Completed |
NCT01218568 -
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
|
N/A |